TRIUMPH-4: Retatrutide Phase 3 trial (NCT05931367)
A Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo-Controlled Trial
Registry record checked
At a glance
- Phase
- Phase 3
- Status
- Completed
- Enrolment
- 445
- actual
- Start
- 1 Aug 2023 (actual)
- Primary completion
- 14 Nov 2025 (actual)
- Sponsor
- Eli Lilly and Company
Design
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Retatrutide Dose 1 | Experimental | Drug: Retatrutide | Participants will receive retatrutide subcutaneously (SC). |
| Retatrutide Dose 2 | Experimental | Drug: Retatrutide | Participants will receive retatrutide SC. |
| Placebo | Placebo comparator | Drug: Placebo | Participants will receive placebo. |
Endpoints
Primary endpoint
| Measure | Time frame |
|---|---|
| Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score | Baseline, Week 68 |
| Percent Change from Baseline in Body Weight | Baseline, Week 68 |
Endpoints
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Change from Baseline in the WOMAC Physical Function Subscale Score | Baseline, Week 68 |
| Change from Baseline in Waist Circumference | Baseline, Week 68 |
| Percent Change from Baseline in Total Cholesterol | Baseline, Week 68 |
| Percent Change from Baseline in Triglycerides | Baseline, Week 68 |
| Change from Baseline in Body Mass Index (BMI) | Baseline, Week 68 |
| Change from Baseline in Systolic Blood Pressure (SBP) | Baseline, Week 68 |
| Change from Baseline in Diastolic Blood Pressure (DBP) | Baseline, Week 68 |
| Percent Change from Baseline in Fasting Insulin | Baseline, Week 68 |
| Change from Baseline in Short Form 36-Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score | Baseline, Week 68 |
| Change from Baseline in Average Pain Intensity Numeric Rating Score (API-NRS) Score | Baseline, Week 68 |
| Change from Baseline in Worst Pain Intensity Numeric Rating Score (WPI-NRS) Score | Baseline, Week 68 |
Eligibility
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- Not stated
Results
Results
No results posted on ClinicalTrials.gov as of 2 Oct 2026.
Sources
- 1A Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo-Controlled TrialClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
Found an error? Report a correction.